| 詳細情報 |  |
|---|---|
| 関連リンク |  |
| 探す |  |
論文 (128件)
- Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, Yasushi Fukuda, Akihiro Bessho, Tadaaki Yamada, Yukihiro Toi, Tomoki Kimura, Hiroshige Yoshioka, Koichi Azuma, et al. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50. JTO clinical and research reports. 2025. 6. 3. 100784-100784
- Daiki Murata, Koichi Azuma, Yuuya Nishii, Kenta Murotani, Goushi Matama, Akihiko Kawahara, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino. The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. 2025. 1-7
- Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, Hiroshige Yoshioka, Takehiro Uemura, Yuko Tsuchiya-Kawano, Seiya Esumi, Takashi Kurosaki, Yuki Sato, Tomohiro Sakamoto, et al. A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025
- Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, Kazuma Kishi, Takahiro Yoshizawa, Takaaki Tokito, Koichi Azuma, Kei Morikawa, Satoshi Igawa, Yusuke Okuma, et al. A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025
- Yosuke Kakiuchi, Koichi Saruwatari, Kenta Murotani, Takaaki Tokito, Toyohisa Iriki, Jun Iwakawa, Yoshihiko Sakata, Naoki Shingu, Sho Saeki, Megumi Inaba, et al. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study. Clinical lung cancer. 2024. 25. 8. 661-671
- Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Hidetoshi Hayashi, Koichi Azuma, Satoshi Hara, Seiji Niho, Ryo Morita, et al. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Respiratory medicine. 2024. 12. 11. 877-887
- Hirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, et al. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO clinical and research reports. 2024. 5. 11. 100716-100716
- Yuki Kato, Hibiki Udagawa, Shingo Matsumoto, Hiroki Izumi, Yuichiro Ohe, Terufumi Kato, Kazumi Nishino, Shingo Miyamoto, Sachiko Kawana, Kenichi Chikamori, et al. Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands). 2024. 197. 107992-107992
- Kiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, Makoto Nishio, Kenichi Chikamori, Eiki Ichihara, Yasutaka Watanabe, Takayuki Asato, Tadayuki Kitagawa, Robert J Fram, et al. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. International journal of clinical oncology. 2024. 29. 10. 1461-1474
- Takehiko Manabe, Masatoshi Kanayama, Hiroki Matsumiya, Katsuma Yoshimatsu, Masataka Mori, Natsumasa Nishizawa, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Koichi Azuma, et al. A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement. General Thoracic and Cardiovascular Surgery Cases. 2024. 3. 1. 44-44
- Daiki Murata, Koichi Azuma, Kenta Murotani, Akihiko Kawahara, Yuuya Nishii, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino. Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy. Cancer immunology, immunotherapy : CII. 2024. 73. 11. 214-214
- Takayuki Horii, Jun Sasaki, Hidenobu Ishii, Misa Sudou, Reiko Takaki, Takaaki Tokito, Koichi Azuma, Tomoaki Hoshino. Thoracic Angiosarcoma Arising from Chronic Tuberculous Pyothorax: A Case Report. Internal medicine (Tokyo, Japan). 2024
- Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, et al. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines. 2024. 12. 8
- Hisao Imai, Takashi Kijima, Koichi Azuma, Kazuma Kishi, Haruhiro Saito, Teppei Yamaguchi, Junko Tanizaki, Yasuto Yoneshima, Kohei Fujita, Satoshi Watanabe, et al. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study. Japanese journal of clinical oncology. 2024. 54. 4. 452-462
- Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga, Koichi Azuma, Hirotaka Matsumoto, Osamu Hataji, Kazumi Nishino, Masahide Mori, et al. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology. 2024. 10. 3. 315-324
- Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, et al. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications. 2024. 4. 1. 226-235
- Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, et al. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO clinical and research reports. 2024. 5. 1. 100613-100613
- Huihui Xiang, Rika Kasajima, Koichi Azuma, Tomoyuki Tagami, Asami Hagiwara, Yoshiro Nakahara, Haruhiro Saito, Yuka Igarashi, Feifei Wei, Tatsuma Ban, et al. Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma. Frontiers in immunology. 2024. 15. 1361992-1361992
- Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, et al. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. Cancer medicine. 2023. 12. 23. 21097-21110
- Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Takayasu Kurata, Shunichi Sugawara, Yoshimasa Shiraishi, Shunsuke Teraoka, Koichi Azuma, et al. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA oncology. 2023. 9. 11. 1505-1513
前のページに戻る
